Intervacc AB (IVACC) AI Stock Analysis

Intervacc AB

(Nasdaq OMX AB:IVACC)

Select Model

Rating:41Neutral

Price Target:SEK 0.74▼(-3.66% Downside)

Action:reiterated

Date:08/21/26

The overall score is driven mainly by very weak profitability and cash generation, which outweigh the benefit of a conservative balance sheet, while negative technical momentum and the absence of earnings or dividend support further constrain the stock’s attractiveness.

Positive Factors

Low leverageVery low leverage limits interest and refinancing pressure, giving Intervacc more flexibility than a highly indebted biotech. This conservative capital structure can help preserve operating capacity during continued development and commercialization efforts, although it does not by itself solve losses or cash use.

Negative Factors

Persistent unprofitabilityNegative gross profit and large operating losses indicate that the current commercial model is not yet covering product and operating costs. Without a sustained improvement in margins, ongoing losses can constrain reinvestment, weaken returns, and increase the need for external capital.

Intervacc AB (IVACC) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 263.11M
Dividend Yield: ―
Average Volume (3M): 295.43K
Price to Earnings (P/E): -2.9
Beta (1Y): 0.37
Revenue Growth: -0.71%
EPS Growth: 54.16%
Country: Sweden
Employees: 16
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Intervacc AB Business Overview & Revenue Model

Company Description

Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including h...

How the Company Makes Money

Intervacc makes money primarily by selling its veterinary vaccine product(s). Revenue is generated through commercialization of its marketed canine vaccine (sold to veterinary clinics and animal health distributors/wholesalers, depending on market),...

Intervacc AB Financial Statement Overview

Summary

Financial performance is weak: revenues remain small and volatile, margins are deeply negative, operating and free cash flows are consistently negative, and returns on equity are persistently below zero, partially offset by a low‑leverage balance sheet.

Income Statement

24Negative

Balance Sheet

58Neutral

Cash Flow

26Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	18.11M	20.09M	11.79M	8.02M	9.68M	5.24M
Gross Profit	-71.88M	-67.41M	-3.53M	-13.81M	3.37M	6.25M
EBITDA	-76.15M	-66.25M	-58.75M	-68.98M	-43.17M	-23.15M
Net Income	-91.75M	-80.81M	-75.52M	-102.85M	-64.16M	-29.38M
Balance Sheet
Total Assets	266.68M	294.43M	187.32M	259.61M	265.04M	329.39M
Cash, Cash Equivalents and Short-Term Investments	127.64M	160.89M	34.40M	88.34M	45.70M	115.71M
Total Debt	866.00K	108.00K	145.00K	181.00K	322.00K	433.00K
Total Liabilities	33.62M	19.52M	24.99M	21.68M	14.88M	21.14M
Stockholders Equity	233.06M	274.91M	162.33M	237.93M	250.16M	308.25M
Cash Flow
Free Cash Flow	-67.48M	-66.92M	-53.90M	-47.94M	-75.92M	-48.67M
Operating Cash Flow	-65.64M	-65.79M	-53.20M	-45.83M	-69.79M	-25.46M
Investing Cash Flow	-9.59M	-1.13M	-706.00K	-2.11M	-6.13M	-23.13M
Financing Cash Flow	818.00K	193.40M	-36.00K	90.58M	5.91M	50.00K

Intervacc AB Technical Analysis

Technical Analysis SentimentNegative

Last Price0.77

Price Trends

50DMA0.96Negative

100DMA1.10Negative

200DMA1.03Negative

Market Momentum

MACD-0.05Positive

RSI30.53Neutral

STOCH4.87Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IVACC, the sentiment is Negative. The current price of 0.77 is below the 20-day moving average (MA) of 0.85, below the 50-day MA of 0.96, and below the 200-day MA of 1.03, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 30.53 is Neutral, neither overbought nor oversold. The STOCH value of 4.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:IVACC.

Intervacc AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:IVACC against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CANTA	70Outperform	SEK 451.68M	2.53	63.09%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:BINV	47Neutral	SEK 357.32M	-0.58	-128.54%	―	-83.67%	-50.29%
SE:IMMU	43Neutral	SEK 348.89M	-3.03	-18.05%	―	―	15.97%
SE:IVACC	41Neutral	SEK 263.11M	-2.89	-34.25%	―	-0.71%	54.16%
SE:EXPRS2	40Underperform	SEK 36.86M	-0.14	-104.71%	―	-2.29%	55.71%
SE:ATORX	37Underperform	SEK 35.32M	-0.02	-439.98%	―	-99.33%	64.90%

* Healthcare Sector Average

Performance Comparison

SE:IVACC and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:IVACC	Intervacc AB	0.77	-0.20	-20.81%
SE:ATORX	Alligator Bioscience AB	0.01	-0.36	-96.77%
SE:BINV	BioInvent International AB	4.30	-28.85	-87.03%
SE:EXPRS2	ExpreS2ion Biotech Holding AB	0.99	-4.93	-83.25%
SE:IMMU	Immunicum AB	5.43	-1.97	-26.62%
SE:CANTA	Cantargia AB	1.72	-1.56	-47.56%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 21, 2026

Intervacc AB AI Stock Analysis